Download
s40256-022-00525-w.pdf 1,35MB
WeightNameValue
1000 Titel
  • Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study
1000 Autor/in
  1. Abumayyaleh, Mohammad |
  2. Demmer, Jonathan |
  3. Krack, Carina |
  4. Pilsinger, Christina |
  5. El-Battrawy, Ibrahim |
  6. Behnes, Michael |
  7. Aweimer, Assem |
  8. Mügge, Andreas |
  9. Lang, Siegfried |
  10. Akin, Ibrahim |
1000 Verlag
  • Springer International Publishing
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-03-30
1000 Erschienen in
1000 Quellenangabe
  • 22(5):535-544
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40256-022-00525-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468101/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched.!##!Aim!#!We aimed to investigate the hemodynamic effects of sacubitril/valsartan among patients with HFrEF.!##!Methods!#!Between 2016 and 2020, we retrospectively collected data for patients with HFrEF treated at the University Medical Center Mannheim, Germany. Data for 240 patients with HFrEF were available. We systematically analyzed echocardiographic parameters, all-cause hospitalization, and congestion rate.!##!Results!#!The left ventricular ejection fraction (LVEF) improved from a median (minimum; maximum) of 28% (3; 65) before initiation of sacubitril/valsartan to a median of 34% (13; 64) at 24-month follow-up (p < 0.001). Systolic pulmonary atrial pressure (PAPsys) decreased from a median of 30 mmHg (13; 115) to 25 mmHg (20; 80) at 24-month follow-up (p = 0.005). The median (minimum; maximum) tricuspid annular plane systolic excursion improved from 17 mm (3; 31) at baseline to 20 mm (9; 30) at 12-month follow-up (p = 0.007). The incidence of severe and moderate mitral, tricuspid, and aortic valvular insufficiency improved after treatment. Hospitalization and congestion rates reduced at 24-month follow-up. The mortality rate in echocardiographic and functional nonresponders was higher than in responders (12.1 vs. 5.2%; p = 0.1 and 11.3 vs. 3.1%; p = 0.01, respectively).!##!Conclusion!#!Follow-up 24 months after starting treatment with sacubitril/valsartan revealed sustained improvements in echocardiographic parameters, including LVEF, PAPsys, and cardiac valvular insufficiency. Rates of all-cause hospitalization and congestion had decreased significantly at follow-up. The mortality rate was higher in echocardiographic and functional nonresponders.
1000 Sacherschließung
lokal Valsartan/pharmacology [MeSH]
lokal Pharmacology/Toxicology
lokal Aminobutyrates [MeSH]
lokal Ventricular Function, Left [MeSH]
lokal Angiotensin Receptor Antagonists/therapeutic use [MeSH]
lokal Drug Combinations [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Heart Failure [MeSH]
lokal Valsartan/therapeutic use [MeSH]
lokal Tetrazoles/adverse effects [MeSH]
lokal Biphenyl Compounds/therapeutic use [MeSH]
lokal Ventricular Dysfunction, Left/drug therapy [MeSH]
lokal Cardiology
lokal Stroke Volume [MeSH]
lokal Hemodynamics [MeSH]
lokal Original Research Article
lokal Biphenyl Compounds/pharmacology [MeSH]
lokal Angiotensin Receptor Antagonists/pharmacology [MeSH]
lokal Pharmacotherapy
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-4766-5523|https://frl.publisso.de/adhoc/uri/RGVtbWVyLCBKb25hdGhhbg==|https://frl.publisso.de/adhoc/uri/S3JhY2ssIENhcmluYQ==|https://frl.publisso.de/adhoc/uri/UGlsc2luZ2VyLCBDaHJpc3RpbmE=|https://frl.publisso.de/adhoc/uri/RWwtQmF0dHJhd3ksIElicmFoaW0=|https://frl.publisso.de/adhoc/uri/QmVobmVzLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/QXdlaW1lciwgQXNzZW0=|https://frl.publisso.de/adhoc/uri/TcO8Z2dlLCBBbmRyZWFz|https://frl.publisso.de/adhoc/uri/TGFuZywgU2llZ2ZyaWVk|https://frl.publisso.de/adhoc/uri/QWtpbiwgSWJyYWhpbQ==
1000 Hinweis
  • DeepGreen-ID: ebb6a2537f8b482795eaa910cc7f121e ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6486338.rdf
1000 Erstellt am 2024-10-03T01:11:35.461+0200
1000 Erstellt von 322
1000 beschreibt frl:6486338
1000 Zuletzt bearbeitet 2024-10-04T13:56:42.840+0200
1000 Objekt bearb. Fri Oct 04 13:56:42 CEST 2024
1000 Vgl. frl:6486338
1000 Oai Id
  1. oai:frl.publisso.de:frl:6486338 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source